Orexin receptor antagonists: Medicinal chemistry and therapeutic potential

Current Topics in Medicinal Chemistry

Volumn 8, Issue 11, 2008, Pages 977-987

  Roecker, Anthony J ^a   Coleman, Paul J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Almorexant; Cataplexy; GPCR; Hypocretin; Insomnia; Orexin; OX1R; OX2R

Indexed keywords

1 (2 METHYL 6 BENZOXAZOLYL) 3 (1,5 NAPHTHYRIDIN 4 YL)UREA; 4 PHENYL 1,3 DIOXANE UREA DERIVATIVE; ACT 078573; ALMOREXANT; BENZAZEPINE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; GW 649898; NEUROPEPTIDE; OREXIN; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; OREXIN A; OREXIN B; OREXIN RECEPTOR ANTAGONIST; PYRAZOLE DERIVATIVE; RECEPTOR BLOCKING AGENT; SB 649868; SB 674042; SEDATIVE AGENT; TETRAHYDROISOQUINOLINE DERIVATIVE; UREA DERIVATIVE; ZOLPIDEM;

ANIMAL MODEL; AREA UNDER THE CURVE; BINDING AFFINITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NONHUMAN; RECEPTOR BLOCKING; REPEATED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; SLEEP TIME; SLEEP WAKING CYCLE; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

HUMANS; HYPNOTICS AND SEDATIVES; MOLECULAR STRUCTURE; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROPEPTIDE; SLEEP INITIATION AND MAINTENANCE DISORDERS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 48249109864     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802608784936746     Document Type: Review

References (45)

1. Ohno, K.; Sakurai, T. Orexin neuronal circuitry: Role of the regulation of sleep and wakefulness. Frontiers in Neuroendocrinology 2009, 29, 70-87.
2. (a) de Lecea, L.; Kilduff, T. S.; Peyron, C.; Gao, X.; Foye, P. E.; Danielson, P. E.; Fukuhara, C.; Battenberg, E. L. F.; Gautvik, V. T.; Bartlett II, F. S.; Frankel, W. N.; van den Pol, A. N.; Bloom, F. E.; Gautvik, K. M.; Sutcliffe, J. G. The hypocretins: Hypothalarmus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. USA 1998, 95, 322-327.
3. (b) Sakurai, T.; Amemiya, A.; Ishii, M.; Matsuzaki, I.; Chemelli, R. M.; Tanaka, H.; Williams, S. C.; Richardson, J. A.; Kozlowski, G. P.; Wilson, S.; Arch, J. R. S.; Buckingham, K. E.; Haynes, A. C.; Carr, S. A.; Annan, R. S.; McNulty, D. E.; Liu, W.; Terrett, J. A.; Elshourbagy, N. A.; Bergsma, D. J.; Yanagisawa, M. Orexins, and orexin receptors: A family of hypothalamic neuropeptides and G-protein receptors that regulate feeding behavior. Cell 1998, 92, 573-585
4. Sakurai, T.; Moriguchi, T.; Furuya, K.; Kajiwara, N.; Nakamura, T.; Yanagisawa, M.; Goto, K. Structure and function of human prepro-orexin gene. J. Biol. Chem. 1999, 25, 17771-17776.
5. (a) Hagan, J. J.; Leslie, R. A.; Patel, S.; Evans, M. L.; Wattam, T. A.; Holmes, S.; Benham, C. D.; Taylor, S. G.; Routledge, C.; Hemmati, P.; Munton, R. P.; Ashmeade, T. E.; Shah, A. S.; Hatcher, J. P.; Hatcher, P. D.; Jones, D. N. C.; Smith, M. I.; Piper, D. C.; Hunter, A. J.; Porter, R. A.; Upton, N. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc. Natl. Acad. Sci. USA 1999, 96, 10911-10916.
6. (b) Harris, G. C. Wimmer, M.; Aston-Jones, G. A role for lateral hypothalamic orexin neurons in reward seeking. Nature 2005, 437, 556-559.
7. Lin, L.; Faraco, J.; Li, R.; Kadotani, H.; Rogers, W.; Lin, X.; Qiu, X.; de Jong, P.; Nishino, S.; Mignot, E. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin receptor 2 gene. Cell 1999, 98, 365-376.
8. Chemelli, R. M.; Willie, J. T.; Sinton, C. M.; Elmquist, J. K.; Scammell, T.; Lee, C.; Richardson, J. A.; William, S. C.; Xiong, Y.; Kisanuki, Y.; Fitch, T. E.; Nakazato, M.; Hammer, R. E.; Saper, C. B.; Yanagisawa, M. Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation. Cell 1999, 98, 437-451.
9. Willie, J. T.; Chemelli, R. M.; Sinton, C. M.; Tokita, S.; Williams, S. C.; Kisanuki, Y. Y.; Marcus, J. N.; Lee, C.; Elmquist, J. K.; Kohlmeier, K. A.; Leonard, C. S.; Richardson, J. A.; Hammer, R. E., Yanagisawa, M. Distinct narcolepsy syndromes in orexin receptor-2 and orexin mill mice: molecular genetic dissection of non-REM and REM sleep regulatory processes. Neuron 2003, 38, 715-730.
10. Brisbare-Rock C.; Dingemanse, J.; Koberstein, R.; Hoever, P.; Aissaoui, H.; Flores, S.; Mueller, C.; Nayler, O.; van Gerven, J.; de Haas, S.; Hess, P.; Qiu, C.; Buchmann, S.; Scherz, M.; Weller, T.; Fischli, W.; Clozel, M.; Jenck, F. Promotion of sleep by targeting the orexin system in rats, dogs, and humans. Nat. Med. 2007, 13, 150-155.
11. Actelion presentations, World Sleep Congress, Cairns, Australia, September 3-6, 2007.
12. Ratti, E. GlaxoSmithKline: Investor update 2007, see: http://www.gsk.com/investors/presentations_webcasts07.htm.
13. For reviews concerning setective orexin ligand, see: (a) Cai, J.; Cooke, F. E.; Sherborne, B. S. Antagoinsts of the orexin receptor. Expert Opin. Ther. Patents 2006, 16, 631-646
14. (b) Bingham, M. J.; Cai, J.; Dechan, M. R. Eating, sleeping and rewarding: Orexin receptors and their antagonists. Curr. Opin. Disc. Dev. 2006, 9, 551-559.
15. Compounds described in figures and tables of this manuscript were selected on the basis of data reported either in the primary literature or in patent publications.
16. (a) Aissoui, H.; Clozel, M.; Weller, T.; Koberstein, R.; Sifferlen, T.; Fischli, W. (Actelion Pharmaceuticals Ltd.) The sulfonylamino-acetic acid derivatives, WO-2004033418 (2004).
17. (b) Aissaoui, H.; Boss, C.; Gude, M.; Koberstein, R.; Sifferlen, T.; Zumbrunn Ackline, C. (Actelion Pharmaceuticals Ltd.) Novel sulfonamide compounds, WO-2007116374 (2007).
18. Aissaoui, H.; Clozel, M.; Fischli, W.; Koberstein, R.; Sifferlen, T. (Actelion Pharmaceuticals Ltd.) 7,8,9,10-Tetrahydro-6H-azepino, 6,7,8,9-letrahydro-pyrido and 2,3-dihydro-2H-pyrrolo[2,1-B]- quinazolinone derivatives, WO-2004004733 (2004)
19. Aissoui, H.; Clozel, M.; Welter, T.; Koberstien, R.; Sifferlen, T.; Fischli, W. (Actelion Pharmaceuticals Ltd.) Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists, WO-02051838 (2002).
20. Koberstein, R.; Aissaoui, H.; Bur, D.; Clozel, M.; Fischli, W.; Jenck, F.; Mueller, C.; Nayler, O.; Sifferlen, T.; Treiber, A.; Weller, T. Tetrahydroisoquinotines as orexin receptor antagonist: Strategies for lead optimization by solution-phase chemistry. Chimia 2003, 57, 270-275.
21. Jenck, F.; Fischer, C.; Qiu, C.; Hess, P.; Koberstein, R.; Brisbare-Roch, C. Somnolence induced by pharmacological blockade of both orexin OX1 and OX2 receptors in dogs, World Sleep Congress Poster Presentation, Cairns, Australia, September 3-6, 2007.
22. Brisbare-Roch, C.; Feletti, L.; Koberstein, R.; Nayler, O.; Jenck, F. Transient orexin receptor blockade induces sleep without cataplexy in rats, World Sleep Congress Poster Presentation, Cairns, Australia, September 3-6, 2007.
23. Tafti, M. Reply to "Promotion of sleep by targeting the orexin system in rats, dogs, and humans". Nat. Med. 2007, 13, 525-526.
24. (a) Hoever, P.; de Haas, S.; Winkler, J.; Cavallaro, M.; van Gerven, J.; Dingemanse, J. Entry-into-humans study with almorexant (ACT-078573), a dual orexin receptor antagonist: Tolerability, safety, and pharmacokineties, World Sleep Congress Poster Presentation, Cairns, Australia, September 3-6, 2007.
25. (b) Hoever, P.; de Haas, S.; Choissi, E.; van Gerven, J.; Dingemanse, J. Entry-nito-humans study with almorexant (ACT-078573), a dual orexin receptor antagonist: Pharmacodynamics, World Sleep Congress Poster Presentation, Cairns, Australia, September 3-6, 2007.
26. Dingemanse, J.; Dorffner, G.; Hajak, G.; Benes, H.; Danker,-Hopfe, H.; Polo, O.; Saletu, B.; Barbanoj, M. J.; Pillar, G.; Penzel, T.; Chiossi, E.; Hoever, P. Proof-of-concept study in primary insomnia patients with almorexant (ACT-078573), a dual orexin receptor antagonist, World Sleep Congress Poster Presentation, Cairns, Australia, September 3-6, 2007.
27. (a) Chan, G.; Johns, A.; Jurewicz, A.; Porter, R. A.; Widdowson, K. (SmithKline Beecham PLC) Phenyl urea and phenyl thiourea derivatives as HFGAN72 antagonists, WO-199909024 (1999)
28. (b) Johns, A.; Porter, R. A. (SmithKline Beecham PLC) Phenyl urea and phenyl thiourea derivatives, WO-199958533 (1999).
29. For representative GSK patents, see: (a) Coulton, S.; Johns, A.; Porter, R. A. (SmithKline Beecham PLC) Preparation of phenyl urea and phenyl thiourea derivatives as orexin receptor antagonist, WO-2000047577 (2000);
30. (b) Coulton, S.; Johns, A.; Porter, R. A. (SmithKline Beecham PLC) Preparation of ethylene diamine derivatives as orexin receptor antagonists, WO-2003051872 (2003); (c) Branch, C. L.; Johnson, C. N.; Stemp, G.; Thewlis, K. (SmithKline Beecham PLC) Preparation of piperidines as orexin receptor antagonists, WO-2001096302 (2001).
31. Porter, R. A.; Chan, W. N.; Coulton, S.; Johns, A.; Hadley, M. S.; Widdowson, K.; Jerman, J. C.; Brough, S. J.; Coldwell, M.; Smart, D.; Jewitt, F.; Jeffrey, P.; Austin, N. 1,3-biarylureas as selective non-peptide antagonists of the orexin-1 receptor. Bioorg. Med. Chem. Lett. 2001, 11, 1907-1910.
32. (a) Haynes, A. C-; Jackson, B.; Chapman, H.; Tadyyon, M.; Johns, A.; Porter, R. A.; Arch, J. R. A selective orexin-1 receptor antagonist reduces food consumption in male and female rats. Regul. Pept. 2000, 96, 45-51;
33. (b) Rodgers, R. J.; Halford, J. C.; Nunes de Souza, R. L.; Piper, D. C.; Arch, J. R.; Upton, N.; Porter, R. A.; Johns, A.; Blundell, J. E. SB-334867, a selective orexin-1 receptor antagonist, enhances behavioral satiety and blocks the hyperphagic effect of orexin-A in rats. Eur. J. Neurosci. 2001, 13, 1444-1452
34. (c) Ishii, Y.; Blundell, J. E.; Halford, J. C.; Upton, N.; Porter, R.; Johns, A.; Summerfield, S.; Rogers, R. J. Anorexia and weight loss in male rats 24 hours following single dose treatment with orexin-1 receptor antagonist SB-334867. Behav. Brain Res. 2005, 157, 331-341.
35. 3H]-SB- 674042, a novel nonpeptide antagonist to the human orexin-1 receptor. Br. J. Pharmacol. 2004, 141, 340-346.
36. Ratti, E. GlaxoSmithKline, Investor update 2004, see: Http://www.gsk.com/investors/presentations_webcasts04.htm.
37. Bergman, J. M.; Roecker, A. J., Mercer, S. P.; Bednar, R. A.; Reiss, D. R.; Ransom, R. W.; Harrell, C. M.; Pettibone, D. J.; Lemaire, W.; Murphy, K. L.; Li, C.; Preuksaritinont, T.; Winrow, C. J.; Renger, J. J.; Koblan, K. S.; Hartman, G. D.; Coleman, P. J. Proline bis-amides as potent dual orexin receptor antagonists. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.
38. For reviews on the relevance of Pgp to drug discovery, see: (a) Hochman, J. H.; Yamazaki, M.; Ohe, T.; Lin, J. H. Evaluation of drug interactions with P-glycoprotein in drug discovery: In vitro assessment of the potential for drug-drug interactions with P-glycoprotein. Curr. Drug Metab. 2002, 3, 257-273;
39. (b) Lin, J. H.; Yamakazi, M. Clinical relevance of P-glycoprotein in drug therapy. Drug Metab. Rev. 2003, 35, 417-454
40. Hirose, M.; Egashira, S.; Goto, Y. Takashi, H.; Ohtake, N.; Iwaasa, H.; Hata, M.; Fukami, T.; Kanatani, A,; Yamada, K. N-acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: The first orexin-2 receptor selective non-peptidic antagonist. Bioorg. Med. Chem. Lett. 2003, 13, 4497-4499.
41. Aranyi, P.; Balogh, M.; Batori, S.; Bence, J.; Finet, M.; Kapui, Z.; Philippo, C.; Szabo, T.; Szlavik, Z.; Tomoskozi, Z.; Urban-Szabo, K.; Venier, O. (Sanofi-Aventis) Pyrimidine derivatives as orexin receptor antagonists. WO2005075458 (2005).
42. Aletru, M.; Aranyi, P.; Balogh, M.; Batori, S.; Bence, J.; Bovy, P.; Kapui, Z.; Mikus, E.; Namane, C,; Philippo, C.; Szabo, T.; Tomoskozi, Z.; Urban-Szabo, K. (Sanofi-Aventis) Pyrazole derivatives and use thereof as orexin receptor antagonists. WO2005060959 (2005).
43. (a) Courte-Manche, G.; Despeyroux, P.; Fontaine, E.; Rochard, P.; Serradeil Le Gal, C. (Sanofi-Aventis) Sulfonamide derivatives, their preparation and their therapeutic application, WO2006024779 (2006);
44. (b) Despeyroux, P.; Fontaine, E.; Courte-Manche, G.; Rochard, P.; Serradeil-Le Gal, C. (Sanofi-Aventis) Sulfonamide derivatives, preparation thereof and therapeutic application, WO2007085718 (2007).
45. McAtee, L. C.; Sutton, S. W.; Rudolph, D. A.; Li, X.; Aluisio, L. E.; Phuong, V. K.; Dvorak, C. A.; Lovenberg, T. W.; Carruthers, N. I.; Jones, T. K. Novel substituted 4-phenyl-[1,3]dioxanes: Potent and selective orexin receptor 2 (OX2R) antagonists. Biaorg Med. Chem. Lett. 2004, 14, 4225-4229.